You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

29 search results for: biologics

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Rhinology
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
View more
Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes
expert video

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes

Rhinology
Prof. Hellings discusses the importance of partnering with patients and considering the clinical importance of symptom improvements.
View more
Clinical Management of CRSwNP: Maximizing Symptom Improvement
expert video

Clinical Management of CRSwNP: Maximizing Symptom Improvement

Rhinology
Prof. Fokkens presents recent evidence of biologic effectiveness for CRSwNP from the real-world setting
View more
The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP
expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

Rhinology
Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.
View more
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health
expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

Dermatology
Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.
View more
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD
expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

Dermatology
Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.
View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more
Prurigo Nodularis: The Patient Journey
interactivity

Prurigo Nodularis: The Patient Journey

Dermatology
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
View more
2022: EoE Year in Review
expert video

2022: EoE Year in Review

Gastroenterology
Join Dr. Ikuo Hirano for an informative review of the key scientific advances in EoE from 2022
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Dermatology
Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region